CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
May 25 2022 - 10:33AM
In a release issued under the same headline on Wednesday, May 25th
by Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), please note that
seborrehic in the headline is seborrheic.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing meaningful
innovations in immuno-dermatology, today announced results of a
nationwide survey of adults with seborrheic dermatitis and the
healthcare providers that treat them, designed to better understand
their satisfaction and experience with currently available
treatment options. The online survey was conducted by The Harris
Poll on behalf of Arcutis and included 300 U.S. adults (18+ years)
who have been diagnosed with seborrheic dermatitis, of which 84%
reported their condition to be moderate or severe, and 601 licensed
U.S. healthcare providers, including dermatologists, nurse
practitioners (NPs), and physician assistants (PAs).
The survey found that individuals with seborrheic dermatitis
experienced a lack of satisfaction with current treatment options
and a high daily burden of care. Specifically, only one in four
adults with seborrheic dermatitis that use treatments reported
being very satisfied with the effectiveness of prescription
treatment options. Additionally, the survey found that, on average,
adults with seborrheic dermatitis use six different treatments each
week, including over-the-counter, prescription, and alternative
treatments to manage their symptoms, and spend more than 30 minutes
a day treating their symptoms. Healthcare providers also expressed
limited satisfaction with available therapies for this disease,
with only one in 10 reporting being very satisfied with available
prescription treatment options.
“Seborrheic dermatitis commonly occurs both on sensitive areas
such as the face and on challenging to treat, hair-bearing areas
such as the scalp, making the disease particularly complex to
treat. Compounding this, seborrheic dermatitis is a chronic
condition and often has to be managed over a person’s lifetime,”
said Raj Chovatiya, M.D., Ph.D., Assistant Professor of Dermatology
and Director of the Center for Eczema and Itch at the Northwestern
University Feinberg School of Medicine. “These survey findings
underscore the challenges that individuals with seborrheic
dermatitis experience when trying to manage their condition and
point to the need for new treatment options.”
According to the survey, close to nine in 10 individuals with
seborrheic dermatitis are interested in trying a new treatment
option, with over nine in 10 healthcare providers agreeing new
treatment options are needed. Individuals surveyed would like
treatment options that reduce their most bothersome symptoms
including itch (70%), redness (64%) and flaking (62%).
Additionally, 87% of individuals with seborrheic dermatitis and 97%
of healthcare providers agree that a treatment that would fit into
the hair care routines of individuals with the disease would make
patients lives easier. In fact, nearly nine in 10 patients said
they would be more likely to stick with a treatment plan if it
meant using fewer treatments.
“Seborrheic dermatitis is a common, everyday immune-mediated
skin disease, yet it lacks the attention, education and treatment
options needed to help address the symptoms of the disease,” said
Frank Watanabe, President and Chief Executive Officer, Arcutis.
“Insights such as these are a critical step towards uncovering what
matters most to the millions of individuals who suffer from
seborrheic dermatitis and their healthcare providers.”
About the SurveyThe patient survey was
conducted online by The Harris Poll on behalf of Arcutis
Biotherapeutics among 300 U.S. adults 18+ years of age who have
been diagnosed with seborrheic dermatitis by a healthcare provider
(including an oversample to reach 60 who are Black/African
American). The survey was conducted December 14, 2021 through
January 19, 2022. Figures for age, sex, education, race/ethnicity,
region, income, household size, and marital status were weighted
where necessary to bring the data into line with actual proportions
in the population. Black/African American patients were balanced
back to natural fall out among the qualified patients. A propensity
score variable was also included to adjust for respondents’
propensity to be online.
The HCP survey was conducted online by The Harris Poll on behalf
of Arcutis Biotherapeutics among 601 HCPs (including
dermatologists, NPs, and PAs) specializing in dermatology who see
at least 1 patient per week and regularly see 1+ patients with
seborrheic dermatitis per year. The survey was conducted December
16, 2021 through January 19, 2022. For Dermatologists, figures for
years in practice, gender, and region were weighted where necessary
to bring the data into line with actual proportions in the
population. For NP/PAs, raw data were not weighted and are
therefore only representative of the individuals who completed the
survey.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is a medical dermatology company that champions
meaningful innovation to address the urgent needs of patients
living with immune-mediated dermatological diseases and conditions.
With a commitment to solving the most persistent patient challenges
in dermatology, Arcutis harnesses its unique dermatology
development platform coupled with its dermatology expertise to
build differentiated therapies against biologically validated
targets. For more information, visit www.arcutis.com or
follow Arcutis on LinkedIn and Twitter.
Contacts:MediaAmanda Sheldon,
Head of Corporate Communicationsasheldon@arcutis.com
InvestorsEric McIntyre, Head of Investor
Relationsemcintyre@arcutis.com
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1d6f64a9-de26-481b-905c-7681d63a7f7c
https://www.globenewswire.com/NewsRoom/AttachmentNg/dce5a7ad-1702-4227-9ef4-97d343c8e75e
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024